Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
14°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mineralys Therapeutics, Inc. - Common Stock
(NQ:
MLYS
)
11.87
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mineralys Therapeutics, Inc. - Common Stock
Earnings Scheduled For November 11, 2024
November 11, 2024
Via
Benzinga
Insights into Mineralys Therapeutics's Upcoming Earnings
November 08, 2024
Via
Benzinga
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 20, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Mineralys Therapeutics Earnings Preview
March 20, 2024
Via
Benzinga
Where Mineralys Therapeutics Stands With Analysts
May 16, 2023
Via
Benzinga
Where Mineralys Therapeutics Stands With Analysts
March 16, 2023
Via
Benzinga
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 12, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MLYS Investors Have Opportunity to Join Mineralys Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
September 09, 2024
From
Schall Law
Via
GlobeNewswire
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024
August 13, 2024
MLYS stock results show that Mineralys Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024
May 09, 2024
MLYS stock results show that Mineralys Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
March 21, 2024
MLYS stock results show that Mineralys Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 08, 2024
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.
Via
Benzinga
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
February 08, 2024
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 08, 2024
Via
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
September 19, 2023
From
Praxis Bioresearch, Inc.
Via
GlobeNewswire
$5M Bet On TreeHouse Foods? Check Out These 3 Stocks Insiders Are Buying
September 11, 2023
Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
Via
Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
July 17, 2023
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 21, 2023
On Tuesday, 74 companies achieved new lows for the year.
Via
Benzinga
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
March 07, 2023
Via
Benzinga
Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying
February 17, 2023
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
February 14, 2023
During Tuesday, 40 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 13, 2023
On Monday, 42 companies hit new 52-week lows.
Via
Benzinga
There's a Lot to Love About Mineralys' Valentine's Day IPO
February 13, 2023
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Opening Day: Hesai Scores Biggest U.S. Debut By Chinese Company Since Didi
February 11, 2023
Shares of Hesai, a developer of sensor technologies used in self-driving cars, jumped as much as 29% in its first trading day, making the listing the largest by a Chinese issuer in the U.S. since Didi...
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.